Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | CBFB | Q13951 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5738772 | 0.85 | LRRK2 (0.41) | LRRK2KDM4ENPC1PIM1CBFB | |
| SCHEMBL5740644 | 0.85 | LRRK2 (0.41) | LRRK2KDM4ENPC1PIM1CBFB | |
| SCHEMBL5739054 | 0.83 | NUDT1 (0.38) | KDM4EADORA2ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL5249664 | 0.82 | LRRK2 (0.48) | LRRK2KDM4ENPC1PIM1CBFB | |
| SCHEMBL5739772 | 0.80 | LRRK2 (0.43) | LRRK2KDM4ENPC1PIM1CBFB | |
| SCHEMBL5739471 | 0.78 | KDM4E (0.38) | LRRK2KDM4ENPC1PIM1CBFB | |
| SCHEMBL4710475 | 0.78 | KDM4E (0.38) | LRRK2KDM4ENPC1PIM1CBFB | |
| SCHEMBL5739756 | 0.78 | LRRK2 (0.41) | LRRK2KDM4ENPC1PIM1CBFB | |
| SCHEMBL5740335 | 0.78 | LRRK2 (0.41) | LRRK2KDM4ENPC1PIM1CBFB | |
| SCHEMBL4711497 | 0.75 | LRRK2 (0.39) | LRRK2KDM4ENPC1PIM1CBFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132428-B2 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | claimed |
| EP-1644371-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005012301-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-10 | — | — | WO | claimed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | claimed |
| US-7132428-B2 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1644371-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005012301-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | PRKDC, MAP3K2, MAP3K20 | LRRK2 370/4885KDM4E 3336/4885NPC1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.